Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants

Hun Soo Chang, Eunsoo Won, Hwa Young Lee, Byung-Joo Ham, Min-Soo Lee

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is one of the most consistent neuroendocrine abnormalities observed in patients with major depressive disorder (MDD). The peptide corticotropin-releasing hormone (CRH) is a key mediator for HPA axis function during stress. This study evaluated the associations of CRH polymorphisms with susceptibility to MDD and response to antidepressant treatment, and the gene-environment interaction with stressful life events (SLEs). After screening 31 polymorphisms in the gene encoding CRH, we evaluated the association of polymorphisms with MDD susceptibility in 149 patients with MDD and 193 control subjects; in patients, we also evaluated the response to treatment with antidepressants. Although genotypes and haplotypes were not significantly associated with the risk of MDD, non-remitters were more likely to carry haplotype 1 (. ht1) than were remitters (. P=. 0.019-0.038), when only patients without SLE were included; however, the association was not significant after correction for multiple comparisons. Additionally, after 4 and 8 weeks of treatment in patients who experienced no SLEs, significantly higher 21-item Hamilton Depression Rating scores were found in MDD subjects who were CRH ht1 homozygotes compared to patients carrying one or no ht1 alleles (. P=. 0.007 and 0.027 at 4 and 8 weeks, respectively). Although these preliminary observations require further confirmation in future studies, these results on the interaction between CRH haplotypes and SLEs, suggest that CRH ht1 which is moderated by SLEs, may be associated with antidepressant treatment outcomes in patients with MDD.

Original languageEnglish
Pages (from-to)116-124
Number of pages9
JournalBehavioural Brain Research
Volume292
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Corticotropin-Releasing Hormone
Major Depressive Disorder
Antidepressive Agents
Haplotypes
Gene-Environment Interaction
Peptide Hormones
Homozygote
Therapeutics
Alleles
Genotype
Depression
Genes

Keywords

  • Antidepressant
  • Corticotropin releasing hormone
  • Genetic polymorphism
  • Major depressive disorder
  • Treatment outcome

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants. / Chang, Hun Soo; Won, Eunsoo; Lee, Hwa Young; Ham, Byung-Joo; Lee, Min-Soo.

In: Behavioural Brain Research, Vol. 292, 01.10.2015, p. 116-124.

Research output: Contribution to journalArticle

@article{2db0c785c7c34cb2b39b7b02b7dd7ced,
title = "Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants",
abstract = "Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is one of the most consistent neuroendocrine abnormalities observed in patients with major depressive disorder (MDD). The peptide corticotropin-releasing hormone (CRH) is a key mediator for HPA axis function during stress. This study evaluated the associations of CRH polymorphisms with susceptibility to MDD and response to antidepressant treatment, and the gene-environment interaction with stressful life events (SLEs). After screening 31 polymorphisms in the gene encoding CRH, we evaluated the association of polymorphisms with MDD susceptibility in 149 patients with MDD and 193 control subjects; in patients, we also evaluated the response to treatment with antidepressants. Although genotypes and haplotypes were not significantly associated with the risk of MDD, non-remitters were more likely to carry haplotype 1 (. ht1) than were remitters (. P=. 0.019-0.038), when only patients without SLE were included; however, the association was not significant after correction for multiple comparisons. Additionally, after 4 and 8 weeks of treatment in patients who experienced no SLEs, significantly higher 21-item Hamilton Depression Rating scores were found in MDD subjects who were CRH ht1 homozygotes compared to patients carrying one or no ht1 alleles (. P=. 0.007 and 0.027 at 4 and 8 weeks, respectively). Although these preliminary observations require further confirmation in future studies, these results on the interaction between CRH haplotypes and SLEs, suggest that CRH ht1 which is moderated by SLEs, may be associated with antidepressant treatment outcomes in patients with MDD.",
keywords = "Antidepressant, Corticotropin releasing hormone, Genetic polymorphism, Major depressive disorder, Treatment outcome",
author = "Chang, {Hun Soo} and Eunsoo Won and Lee, {Hwa Young} and Byung-Joo Ham and Min-Soo Lee",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.bbr.2015.06.005",
language = "English",
volume = "292",
pages = "116--124",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",

}

TY - JOUR

T1 - Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants

AU - Chang, Hun Soo

AU - Won, Eunsoo

AU - Lee, Hwa Young

AU - Ham, Byung-Joo

AU - Lee, Min-Soo

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is one of the most consistent neuroendocrine abnormalities observed in patients with major depressive disorder (MDD). The peptide corticotropin-releasing hormone (CRH) is a key mediator for HPA axis function during stress. This study evaluated the associations of CRH polymorphisms with susceptibility to MDD and response to antidepressant treatment, and the gene-environment interaction with stressful life events (SLEs). After screening 31 polymorphisms in the gene encoding CRH, we evaluated the association of polymorphisms with MDD susceptibility in 149 patients with MDD and 193 control subjects; in patients, we also evaluated the response to treatment with antidepressants. Although genotypes and haplotypes were not significantly associated with the risk of MDD, non-remitters were more likely to carry haplotype 1 (. ht1) than were remitters (. P=. 0.019-0.038), when only patients without SLE were included; however, the association was not significant after correction for multiple comparisons. Additionally, after 4 and 8 weeks of treatment in patients who experienced no SLEs, significantly higher 21-item Hamilton Depression Rating scores were found in MDD subjects who were CRH ht1 homozygotes compared to patients carrying one or no ht1 alleles (. P=. 0.007 and 0.027 at 4 and 8 weeks, respectively). Although these preliminary observations require further confirmation in future studies, these results on the interaction between CRH haplotypes and SLEs, suggest that CRH ht1 which is moderated by SLEs, may be associated with antidepressant treatment outcomes in patients with MDD.

AB - Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is one of the most consistent neuroendocrine abnormalities observed in patients with major depressive disorder (MDD). The peptide corticotropin-releasing hormone (CRH) is a key mediator for HPA axis function during stress. This study evaluated the associations of CRH polymorphisms with susceptibility to MDD and response to antidepressant treatment, and the gene-environment interaction with stressful life events (SLEs). After screening 31 polymorphisms in the gene encoding CRH, we evaluated the association of polymorphisms with MDD susceptibility in 149 patients with MDD and 193 control subjects; in patients, we also evaluated the response to treatment with antidepressants. Although genotypes and haplotypes were not significantly associated with the risk of MDD, non-remitters were more likely to carry haplotype 1 (. ht1) than were remitters (. P=. 0.019-0.038), when only patients without SLE were included; however, the association was not significant after correction for multiple comparisons. Additionally, after 4 and 8 weeks of treatment in patients who experienced no SLEs, significantly higher 21-item Hamilton Depression Rating scores were found in MDD subjects who were CRH ht1 homozygotes compared to patients carrying one or no ht1 alleles (. P=. 0.007 and 0.027 at 4 and 8 weeks, respectively). Although these preliminary observations require further confirmation in future studies, these results on the interaction between CRH haplotypes and SLEs, suggest that CRH ht1 which is moderated by SLEs, may be associated with antidepressant treatment outcomes in patients with MDD.

KW - Antidepressant

KW - Corticotropin releasing hormone

KW - Genetic polymorphism

KW - Major depressive disorder

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84933051954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933051954&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2015.06.005

DO - 10.1016/j.bbr.2015.06.005

M3 - Article

C2 - 26055202

AN - SCOPUS:84933051954

VL - 292

SP - 116

EP - 124

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

ER -